Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.
Could Marketing in Schools Help Save America’s Health?
Novo Nordisk’s Saxenda to cost $1,000 a month; Boehringer Ingelheim’s drug receives priority review; AbbVie’s hep.-C treatment Viekira Pak generates $231 million in first-quarter sales
Five things for pharma marketers to know: Thursday, April 2
Celltrion expects its Remicade biosimilar to hit the US this year; Vivus cuts its sales force; BMJ accuses Novartis of interfering with clinical trials
Obesity medications still a hard sell
March 17, 2015
6:00 pm
Increased FDA scrutiny has not garnered trust for the new medications.
AstraZeneca, Joslin Diabetes Center ink three-year collaboration
March 11, 2015
4:30 pm
The partners will focus on developing treatments for metabolic disorders.